AI found 12 human proteins that carried mRNA in cells—animals remain untested
DeepDelivery screened the human proteome, nominated 512 candidates and tested 15 new proteins in a modular particle system. Twelve showed detectable delivery in cultured cells; the peer-reviewed work is an early platform result, not evidence of a therapy.
The short version
- What happened
- Two sequence models nominated 512 human proteins; researchers selected 15 new candidates from enriched families and included three known delivery proteins as positive controls.
- Who it affects
- Safer repeatable mRNA delivery could matter for vaccines and therapies, but this study does not show that any candidate is safe or effective in a person. Its immediate impact is a shortlist and engineering method for laboratory researchers.
- What remains unproven
- No animal, human, therapeutic efficacy, biodistribution or long-term safety experiment.
Keep in mind
No animal, human, therapeutic efficacy, biodistribution or long-term safety experiment.
Only 15 of 512 new candidates were selected for validation, and most functional assays used three independent biological replicates.
The modular particle and reporter-cell system may not predict performance with therapeutic cargo or in living tissue.
Government and institutional grants supported the work; patent applications cover reported scaffolds and the senior author holds equity in a related biotechnology company.
Source analysis · 1 linked source. Primary analysed source date: 31 October 2026.
Read the full report · 3 min The evidence, methods, implications and limitations
A proteome-scale search produced testable carriers
An AI-guided screen found human proteins that can help engineered particles carry mRNA into cultured cells. DeepDelivery learned sequence patterns associated with viral capsid proteins, then applied two models across the human proteome. Their overlap produced 512 candidates. Researchers selected 15 new proteins representing enriched families, added three previously reported positive controls and tested all 18 in a modular particle design.
Twelve of the 15 new candidates produced detectable functional delivery, so 15 of 18 proteins worked when the known controls were included. Several came from the TRIM family, better known for antiviral roles. Experiments in HEK293T and liver-derived HepG2 cells measured reporter activation, usually across three independent biological replicates; deletion and perturbation tests linked assembly domains to model predictions.[1]
Human-derived does not yet mean safe or therapeutic
The platform addresses a real design question: carriers made from human proteins might eventually reduce some immune problems associated with repeated delivery. The study also compared inflammatory markers in cell models and human-derived immature dendritic cells. But three replicates, reporter systems and cultured cells cannot establish biodistribution, dose, cargo capacity, durability, toxicity or immune safety in a living organism.
The article is peer reviewed and exposes source data, supplementary files and review history. Its conflicts matter: two authors are named on patent applications covering the reported delivery proteins, and senior author Chao Zhong co-founded and owns equity in Shenzhen PAM2L Biotechnologies. Animal studies with independent replication and direct comparisons against established delivery systems would change the assessment.[1]
The distinction that matters
From sequence screen to cell experiment
The model narrowed a large search; laboratory work determined which candidates actually delivered a reporter cargo.
AI screen
Two models scan human proteins
512 shared candidates
Laboratory test
15 new proteins plus 3 controls
12 new candidates showed detectable delivery
Evidence boundary
Cultured-cell assays, mostly n=3
No animal, patient or treatment result